BAVARIAN NORNAM.DK 10 news, videos and press releases
For more news please use our advanced search feature.
BAVARIAN NORNAM.DK 10 - More news...
BAVARIAN NORNAM.DK 10 - More news...
- Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
- Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
- Bavarian Nordic – Completion of Share Buy-Back Program
- Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
- Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
- Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
- Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
- Bavarian Nordic Upgrades its Financial Guidance for 2024
- Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
- Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
- Canada's Only Single-Dose Cholera Vaccine Available Nationwide
- Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Bavarian Nordic Announces First Half 2024 Results
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
- Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
- Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa
- Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
- Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
- Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
